{
    "clinical_study": {
        "@rank": "83857", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo sublingual solution"
            }, 
            {
                "arm_group_label": "Birch pollen allergen extract", 
                "arm_group_type": "Experimental", 
                "description": "Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of\n      300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior\n      to the birch pollen season and continuing over the birch pollen season compared with placebo\n      for reduction of rhinoconjunctivitis-related symptoms and anti-allergy medication usage."
        }, 
        "brief_title": "Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypersensitivity", 
            "Allergic Rhinitis", 
            "Allergic Conjunctivitis", 
            "Seasonal Allergy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic", 
                "Rhinitis, Allergic, Seasonal", 
                "Hypersensitivity", 
                "Rhinitis", 
                "Stress, Psychological"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic birch pollen-related allergic rhinoconjunctivitis for at least the\n             previous 2 pollen seasons requiring intake of symptomatic treatment.\n\n          -  Sensitization to birch pollen demonstrated by a positive Skin Prick Test to birch\n             pollen with wheal diameter > 3 mm and birch pollen allergens specific IgE levels \u2265\n             0.70 kU/L.\n\n          -  RRTSS based on the previous or on the penultimate birch pollen season \u2265 12 out of a\n             maximum possible score of 18.\n\n          -  Patients with an FEV1 (Forced Expiratory Volume at one second) \u2265 80% of the predicted\n             value.\n\n          -  Patients who are willing to comply with the protocol.\n\n          -  Patients having given a signed informed consent before completing any study related\n             procedure.\n\n        Exclusion Criteria:\n\n          -  Patients with symptoms of rhinitis/rhinoconjunctivitis during the birch pollen season\n             due to any other allergens (except alder and hazel). This includes patients with\n             symptomatic allergic rhinitis/rhinoconjunctivitis due to cat or dog allergens, and\n             living with these animals at home or at risk of frequent contacts with these animals\n             (family, friends etc.) during the course of the study.\n\n          -  Patient who previously received desensitization treatment to birch pollen and/or\n             another Betulaceae sp. (for example hazel or alder) within the previous 5 years.\n\n          -  Patients with ongoing treatment by immunotherapy with another allergen.\n\n          -  Pregnancy (positive pregnancy test), breast-feeding.\n\n          -  Female patients of childbearing potential planning a pregnancy during this study or\n             not using a medically accepted contraceptive method (hormonal birth control [orally,\n             injectable or by implant, for at least 2 months before enrolment], intrauterine\n             device, spermicide used with a male condom, bilateral tubal ligation, diaphragm with\n             spermicide, female condom, monogamous relationship with a vasectomised partner).\n\n          -  Patients planning to move during the study or planning to leave the area during the\n             birch pollen season for more than 1 week (7 consecutive days).\n\n          -  Patients with moderate or severe persistent asthma (GINA 3 or 4).\n\n          -  Patients with seasonal mild persistent asthma (GINA 2) necessitating treatment with\n             inhaled glucocorticosteroids at a dose level greater than 400 mcg budesonide\n             dose-equivalents.\n\n          -  Patients with any nasal or oral condition that could interfere with the efficacy or\n             safety assessments (such as nasal polyposis or oral inflammation).\n\n          -  Patients with severe immune deficiency.\n\n          -  Patients with a past or current disease, which as judged by the Investigator, may\n             affect the patient's participation in or outcome of this study.\n\n          -  Any other disease or condition which would place a patient at undue risk by being\n             included in the study (according to the Investigator's opinion).\n\n          -  Usual contra-indications of immunotherapy such as concomitant beta-blocker therapy\n             whatever the route and/or immunosuppressive drugs.\n\n          -  Patients treated with inhaled/systemic steroids (whatever the indication) within 4\n             weeks prior to Visit 1 (Screening), or with long acting systemic corticosteroids 12\n             weeks before Visit 1 (Screening).\n\n          -  Patients under continuous corticotherapy (inhaled or systemic drugs).\n\n          -  Patients following a strict low sodium diet as the study treatment contains 590 mg of\n             sodium chloride per vial in a 10 mL solution.\n\n          -  Investigators, co-Investigators, as well as their children or spouses and all study\n             collaborators."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "574", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731249", 
            "org_study_id": "VO68.10", 
            "secondary_id": "2010-020693-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Birch pollen allergen extract", 
                "description": "Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years", 
                "intervention_name": "Birch pollen allergen extract", 
                "intervention_type": "Biological", 
                "other_name": "Staloral Birch"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sublingual immunotherapy", 
            "Birch pollen extract solution", 
            "Allergic rhinoconjunctivitis"
        ], 
        "lastchanged_date": "November 22, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Plzen", 
                        "country": "Czech Republic", 
                        "zip": "30100"
                    }, 
                    "name": "Alergologicka ordinace"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "National University Hospital - Allergy Unit 4222"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia", 
                        "zip": "10617"
                    }, 
                    "name": "Merekivi Perearstid O\u00dc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00029"
                    }, 
                    "name": "Helsingin yliopistollinen keskussairaala"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67091"
                    }, 
                    "name": "NHC, H\u00f4pitaux Universitaires de Strasbourg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Universit\u00e4tsmedizin Berlin - Allergie-Centrum-Charit\u00e9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia", 
                        "zip": "1003"
                    }, 
                    "name": "Centre of Investigations and Treatment of Allergic Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilnius", 
                        "country": "Lithuania", 
                        "zip": "08109"
                    }, 
                    "name": "Allergic Diseases Diagnostics and Treatment Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "zip": "90-153"
                    }, 
                    "name": "SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w \u0141odzi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Banska Bystrica", 
                        "country": "Slovakia", 
                        "zip": "975 17"
                    }, 
                    "name": "Imunologicko-alergologicka amb."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00f6teborg", 
                        "country": "Sweden", 
                        "zip": "413 45"
                    }, 
                    "name": "Sahlgrenska Universitetssjukhuset - Avd f\u00f6r Lungmedicin och Allergi"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Denmark", 
                "Estonia", 
                "Finland", 
                "France", 
                "Germany", 
                "Latvia", 
                "Lithuania", 
                "Poland", 
                "Slovakia", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis", 
        "overall_official": {
            "affiliation": "Allergie-Centrum-Charit\u00e9, Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Charit\u00e9 Campus Mitte, Universit\u00e4tsmedizin, Charit\u00e9platz 1, 10117 Berlin, Germany", 
            "last_name": "Margitta WORM, MD, PR", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Medicines Agency", 
                "Estonia: The State Agency of Medicine", 
                "Finland: Finnish Medicines Agency", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Paul-Ehrlich-Institut", 
                "Latvia: State Agency of Medicines", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Poland: Ministry of Health", 
                "Slovakia: State Institute for Drug Control", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Symptom score adjusted on patient's rescue medication usage", 
            "measure": "Average Adjusted Symptom Score", 
            "safety_issue": "No", 
            "time_frame": "Year 2 of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731249"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Average Rhinoconjunctivitis Total Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Average Rescue Medication Score", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Each of Six Individual Average Rhinoconjunctivitis Symptom Scores", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Average Combined Score", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Average Rhinoconjunctivitis Visual Analogue Scale Score", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Average Adjusted Visual Analogue Scale Score", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Rescue Medication Usage", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Proportion of Symptom-controlled Days", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Rhinoconjunctivitis Quality of Life Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Global evaluation of the efficacy by the patient", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "description": "sensitization profile (mono- vs poly-sensitized) is derived from the skin prick test results", 
                "measure": "Sensitization profile", 
                "safety_issue": "No", 
                "time_frame": "Before and after each treatment period (over 2 years)"
            }, 
            {
                "measure": "Asthma", 
                "safety_issue": "No", 
                "time_frame": "Before, during and after each pollen season (over 2 years)"
            }, 
            {
                "measure": "Immunological markers specific for birch pollen", 
                "safety_issue": "No", 
                "time_frame": "Before and after each treatment period (over 2 years)"
            }, 
            {
                "description": "Proportion of days-off due to birch pollen-induced symptoms", 
                "measure": "Economical Evaluation", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "measure": "Wheal diameter of the birch allergen Skin prick test", 
                "safety_issue": "No", 
                "time_frame": "Before and after each treatment period (over 2 years)"
            }, 
            {
                "description": "Analysis on a subset of patients presenting an Oral Allergy Syndrome at study entry", 
                "measure": "Oral Provocation Test", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }, 
            {
                "description": "Analysis on a subset of patients", 
                "measure": "Mucosa Local Inflammation", 
                "safety_issue": "No", 
                "time_frame": "Year 1 of treatment"
            }, 
            {
                "description": "adverse events, physical examination including vital signs and laboratory data described by number of patients in each treatment group", 
                "measure": "Safety assessments", 
                "safety_issue": "Yes", 
                "time_frame": "~20 months"
            }, 
            {
                "measure": "Average adjusted Symptom score analysis by tertiles", 
                "safety_issue": "No", 
                "time_frame": "Year 2 of treatment"
            }
        ], 
        "source": "Stallergenes", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Quintiles", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Aptuit Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Cenduit LLC", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "PHT Corporation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Stallergenes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}